(Q54002311)

23 May 2018

title

Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. (English)

1 reference

23 May 2018

1 reference

Kaplan SA

1

1 reference

23 May 2018

Meade-D'Alisera P

series ordinal

2

1 reference

23 May 2018

Quiñones S

series ordinal

3

1 reference

23 May 2018

Soldo KA

series ordinal

4

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 October 1995

1 reference

23 May 2018

published in

Urology

1 reference

23 May 2018

volume

46

1 reference

23 May 2018

issue

4

1 reference

23 May 2018

page(s)

512-517

1 reference

23 May 2018

1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Sub-Committee

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980264-7

7 January 2021

10.1016/S0090-4295(99)80264-7

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018